{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:39:46Z","timestamp":1792762786986,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["716079 (Predict)"],"award-info":[{"award-number":["716079 (Predict)"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["826121 (iPC)"],"award-info":[{"award-number":["826121 (iPC)"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen kanker","doi-asserted-by":"publisher","award":["STI.VLK.2023.0005.01"],"award-info":[{"award-number":["STI.VLK.2023.0005.01"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["956285 (VAGABOND)"],"award-info":[{"award-number":["956285 (VAGABOND)"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["FWO.OPR.2024.0016.01"],"award-info":[{"award-number":["FWO.OPR.2024.0016.01"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.celrep.2026.117997","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:15:44Z","timestamp":1791850544000},"page":"117997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-092X","authenticated-orcid":false,"given":"Joshua Robert","family":"Goulding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn Tim","family":"Couwenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Lee","family":"Bekaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"De Vloed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Amo-Addae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"De Wyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaat","family":"De Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Vleminckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Eising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlinde L.","family":"van den Boogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Depestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaat","family":"Durinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117997_bib1","doi-asserted-by":"crossref","first-page":"102964","DOI":"10.1016\/j.eclinm.2024.102964","article-title":"Global, regional, and national epidemiology of childhood neuroblastoma (1990\u20132021): a statistical analysis of incidence, mortality, and DALYs","volume":"79","author":"Nong","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.celrep.2026.117997_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng.2529","article-title":"The genetic landscape of high-risk neuroblastoma","volume":"45","author":"Pugh","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1126\/science.6719137","article-title":"Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage","volume":"224","author":"Brodeur","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117997_bib4","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/jpm11121286","article-title":"From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma","volume":"11","author":"Decaesteker","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.celrep.2026.117997_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41588-018-0044-9","article-title":"Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma","volume":"50","author":"Zeid","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.molcel.2019.02.031","article-title":"MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation","volume":"74","author":"Baluapuri","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib7","series-title":"Neuroblastoma","first-page":"23","article-title":"Chapter 2 - Role of Genetic and Epigenetic Alterations in Pathogenesis of Neuroblastoma","author":"Inomistova","year":"2019"},{"key":"10.1016\/j.celrep.2026.117997_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41586-019-1030-9","article-title":"Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase","volume":"567","author":"Herold","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117997_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1747-1028-7-6","article-title":"Two sides of the Myc-induced DNA damage response: from tumor suppression to tumor maintenance","volume":"7","author":"Campaner","year":"2012","journal-title":"Cell Div."},{"key":"10.1016\/j.celrep.2026.117997_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41588-023-01332-y","article-title":"Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome","volume":"55","author":"K\u00f6rber","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib11","article-title":"DNA repair and replicative stress addiction in neuroblastoma","volume":"4","author":"Durinck","year":"2024","journal-title":"EJC Paediatr. Oncol."},{"key":"10.1016\/j.celrep.2026.117997_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112950","volume":"190","author":"Pearson","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib13","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-020-18987-4","article-title":"Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations","volume":"11","author":"Brady","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117997_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s43018-022-00474-y","article-title":"The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations","volume":"4","author":"Villani","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115537","article-title":"DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition","volume":"44","author":"Hayes","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/jnci\/djad182","article-title":"BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma","volume":"116","author":"Randall","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2026.117997_bib17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jnci\/djad183","article-title":"Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival","volume":"116","author":"Kim","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.celrep.2026.117997_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.tcb.2019.06.005","article-title":"Defining and Modulating \u2018BRCAness","volume":"29","author":"Byrum","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.tig.2024.04.013","article-title":"(Single-stranded DNA) gaps in understanding BRCAness","volume":"40","author":"Schreuder","year":"2024","journal-title":"Trends Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1056\/NEJMc2403316","article-title":"Response to PARP Inhibition in a BARD1-Mutated Refractory Neuroblastoma","volume":"391","author":"Cupit-Link","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117997_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00642","article-title":"Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis","volume":"10","author":"Gatz","year":"2026","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.celrep.2026.117997_bib23","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847592","article-title":"CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes","volume":"20","author":"Chirackal Manavalan","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf8698","article-title":"CDK12 and Integrator-PP2A complex modulates LEO1 phosphorylation for processive transcription elongation","volume":"9","author":"Qiu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2026.117997_bib25","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2026.117997_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117997_bib27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117997_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.celrep.2015.12.025","article-title":"Structural and Functional Analysis of the Cdk13\/Cyclin K Complex","volume":"14","author":"Greifenberg","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz5041","article-title":"CDK13 cooperates with CDK12 to control global RNA polymerase II processivity","volume":"6","author":"Fan","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2026.117997_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn7625","article-title":"Oncogenic CDK13 mutations impede nuclear RNA surveillance","volume":"380","author":"Insco","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117997_bib31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","article-title":"Rational discovery of molecular glue degraders via scalable chemical profiling","volume":"16","author":"Mayor-Ruiz","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41589-021-00765-y","article-title":"Discovery and resistance mechanism of a selective CDK12 degrader","volume":"17","author":"Jiang","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic Targeting of CDK12\/CDK13 in Triple-Negative Breast Cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","article-title":"The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma","volume":"9","author":"Houles","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.celrep.2026.117997_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105501","article-title":"The reversible inhibitor SR-4835 binds Cdk12\/cyclin K in a noncanonical G-loop conformation","volume":"300","author":"Schmitz","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2026.117997_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102971","article-title":"Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma","volume":"59","author":"George","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2026.117997_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ccell.2019.10.012","article-title":"Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12\/13 Inhibitor Improves Chemotherapy","volume":"36","author":"Hopkins","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib39","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41388-023-02930-0","article-title":"NELF and PAF1C complexes are core transcriptional machineries controlling colon cancer stemness","volume":"43","author":"Aoki","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117997_bib40","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ijc.30864","article-title":"Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer","volume":"141","author":"Schecher","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn1382","article-title":"RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition","volume":"8","author":"Nunes","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2026.117997_bib42","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/0008-5472.CAN-22-2042","article-title":"HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype","volume":"83","author":"Xu","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib43","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/ng.3899","article-title":"Neuroblastoma is composed of two super-enhancer-associated differentiation states","volume":"49","author":"van Groningen","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib44","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1158\/1078-0432.CCR-14-2024","article-title":"Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment","volume":"21","author":"Lambertz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib45","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1091\/mbc.02-02-0030","article-title":"Identification of genes periodically expressed in the human cell cycle and their expression in tumors","volume":"13","author":"Whitfield","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib46","doi-asserted-by":"crossref","first-page":"7314","DOI":"10.1038\/s41467-021-27530-y","article-title":"R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability","volume":"12","author":"Mosler","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117997_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105784","article-title":"THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate","volume":"26","author":"Polenkowski","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.celrep.2026.117997_bib48","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1038\/s41467-024-51229-5","article-title":"CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts","volume":"15","author":"Curti","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117997_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02773-3","article-title":"Pan-cancer analysis of non-oncogene addiction to DNA repair","volume":"11","author":"Berm\u00fadez-Guzm\u00e1n","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib50","doi-asserted-by":"crossref","first-page":"19190","DOI":"10.1073\/pnas.1208215109","article-title":"Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification","volume":"109","author":"Valentijn","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117997_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1101\/gad.322339.118","article-title":"CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability","volume":"33","author":"Choi","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2026.117997_bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117997_bib53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The Toxicity of Poisons Applied Jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gutjnl-2019-318506","article-title":"CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.celrep.2026.117997_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317727479","article-title":"BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors","volume":"39","author":"Paculov\u00e1","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib56","unstructured":"MedchemExpress.com [Internet]. [cited 2026 Apr 30]. SR-4835 | CDK12\/13 Inhibitor | MedChemExpress. Available from: https:\/\/www.medchemexpress.com\/sr-4835.html"},{"key":"10.1016\/j.celrep.2026.117997_bib57","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/1538-7445.AM2023-1635","article-title":"Abstract 1635: OKI-1546 is a selective, orally bioavailable inhibitor of CDK12 that causes tumor regression in multiple preclinical cancer models","volume":"83","author":"Strait","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114542","article-title":"Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update","volume":"239","author":"Engle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117997_bib59","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/bjc.2014.325","article-title":"Structurally diverse MDM2\u2013p53 antagonists act as modulators of MDR-1 function in neuroblastoma","volume":"111","author":"Chen","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib60","doi-asserted-by":"crossref","first-page":"23962","DOI":"10.1021\/acs.jmedchem.5c01271","article-title":"Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in Neuroblastoma","volume":"68","author":"Krols","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117997_bib61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-4889(96)00040-7","article-title":"Expression of the human RAD51 gene during the cell cycle in primary human peripheral blood lymphocytes","volume":"1312","author":"Flygare","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.celrep.2026.117997_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng837","article-title":"BRCA1 regulates the G2\/M checkpoint by activating Chk1 kinase upon DNA damage","volume":"30","author":"Yarden","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib63","article-title":"The Homologous Recombination Machinery Orchestrates Post-replication DNA Repair During Self-renewal of Mouse Embryonic Stem Cells","volume":"7","author":"Choi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41418-025-01566-9","article-title":"BRCA1 and BRCA2 gene expression: p53- and cell cycle-dependent repression requires RB and DREAM","volume":"33","author":"Quaas","year":"2026","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.celrep.2026.117997_bib65","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","article-title":"ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity","volume":"9","author":"Munshi","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2026.117997_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13058-023-01648-x","article-title":"Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors","volume":"25","author":"van der Noord","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib67","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/2767-9764.CRC-23-0370","article-title":"E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network","volume":"4","author":"Poliakov\u00e1 Turan","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.celrep.2026.117997_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1541-7786.MCR-16-0157","article-title":"AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers","volume":"15","author":"Balaji","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib69","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.hlife.2024.01.003","article-title":"Discoidin domain receptor 1 as a potent therapeutic target in solid tumors","volume":"2","author":"Bibi","year":"2024","journal-title":"hLife"},{"key":"10.1016\/j.celrep.2026.117997_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35784","article-title":"Targeting ROS1 Rearrangements in Non\u2013Small Cell Lung Cancer: Current Insights and Future Directions","volume":"131","author":"Desilets","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib71","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41388-021-01661-4","article-title":"MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma","volume":"40","author":"Ke","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117997_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2013.05.203","article-title":"TRK-signaling, notch mutations and PTEN loss converge on mTOR in T-ALL and cause addiction to cap dependent mRNA translation","volume":"41","author":"Schwarzer","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.celrep.2026.117997_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.723137","article-title":"Emerging Role of E2F Family in Cancer Stem Cells","volume":"11","author":"Xie","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.celrep.2026.117997_bib74","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41523-018-0091-5","article-title":"mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential","volume":"4","author":"Faham","year":"2018","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib75","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1177\/1947601910388030","article-title":"MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest","volume":"1","author":"Medov\u00e1","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib76","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s41388-023-02714-6","article-title":"A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response","volume":"42","author":"Koch","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117997_bib77","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s42003-023-05045-0","article-title":"The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer","volume":"6","author":"Yeo","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam8216","article-title":"CDK12-mediated transcriptional regulation of noncanonical NF-\u03baB components is essential for signaling","volume":"11","author":"Henry","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2026.117997_bib79","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ng1861","article-title":"A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers","volume":"38","author":"Carter","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117997_bib80","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-022-00427-8","article-title":"Development of a novel BRCAness score that predicts response to PARP inhibitors","volume":"10","author":"Oshi","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.celrep.2026.117997_bib81","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1038\/onc.2016.14","article-title":"HGF\/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes","volume":"35","author":"Cui","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117997_bib82","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.bbagrm.2014.09.016","article-title":"FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance","volume":"1839","author":"Zona","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.celrep.2026.117997_bib83","first-page":"2635","article-title":"Tyrosine Kinase Inhibitor-Induced Defects in DNA Repair Sensitize FLT3(ITD)-Positive Acute Myeloid Leukemia Quiescent and Proliferative Cells to PARP Inhibitors","volume":"130","author":"Maifrede","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117997_bib84","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.18632\/oncotarget.6644","article-title":"Cell cycle-dependent resolution of DNA double-strand breaks","volume":"7","author":"Ambrosio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117997_bib85","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib86","doi-asserted-by":"crossref","first-page":"57525","DOI":"10.18632\/oncotarget.10544","article-title":"Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors","volume":"7","author":"Vaughan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117997_bib87","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41420-022-00963-0","article-title":"EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma","volume":"8","author":"Voeltzke","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.celrep.2026.117997_bib88","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41598-017-01729-w","article-title":"Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib89","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib90","article-title":"CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13","volume":"5","author":"Tien","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.celrep.2026.117997_bib91","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13046-023-02790-2","article-title":"MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma","volume":"42","author":"Pitolli","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib92","first-page":"RP100081","article-title":"Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies","volume":"26","author":"Frank","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2026.117997_bib93","unstructured":"DepMap 24Q4 Public [Internet] Figshare+; 2024 [cited 2025 Apr 17]. Available from: https:\/\/plus.figshare.com\/articles\/dataset\/DepMap_24Q4_Public\/27993248\/1 doi:10.25452\/figshare.plus.27993248.v1"},{"key":"10.1016\/j.celrep.2026.117997_bib94","unstructured":"Data | DepMap Portal [Internet]. [cited 2025 Apr 15]. Available from: https:\/\/depmap.org\/portal"},{"key":"10.1016\/j.celrep.2026.117997_bib95","article-title":"Development of an orally bioavailable CDK12\/13 degrader and induction of synthetic lethality with AKT pathway inhibition","volume":"5","author":"Chang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.celrep.2026.117997_bib96","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","article-title":"Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12\/13 PROTAC Degrader","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117997_bib97","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1021\/acs.jmedchem.5c00127","article-title":"Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12\/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117997_bib98","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1158\/1535-7163.MCT-25-0954","article-title":"A novel CDK12 inhibitor induces homologous recombination deficiency to enhance PARP inhibitor efficacy in uterine serous carcinoma","volume":"25","author":"Kawahara","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2026.117997_bib99","unstructured":"Carrick Therapeutics Limited. A Modular, Multi-Part, Multi-Arm, Phase 1\/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination With Anticancer Treatments in Participants With Solid Malignancies [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Oct [cited 2026 Apr 30]. Clinical trial registration no.: NCT06600789. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06600789"},{"key":"10.1016\/j.celrep.2026.117997_bib100","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib101","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","article-title":"EWS\/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma","volume":"33","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib102","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/PO.20.00400","article-title":"Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel","volume":"5","author":"Bae","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.celrep.2026.117997_bib103","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors","volume":"30","author":"Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44993-9","article-title":"Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series","volume":"13","author":"De Ioris","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib105","first-page":"3253","article-title":"Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma","volume":"54","author":"Dole","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib106","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1038\/s41467-022-34179-8","article-title":"CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma","volume":"13","author":"Houles","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117997_bib107","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s43018-024-00848-4","article-title":"Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer","volume":"5","author":"Yang","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib108","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1158\/1078-0432.CCR-13-1758","article-title":"Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET","volume":"19","author":"Wu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib109","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","article-title":"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models","volume":"31","author":"Yan","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.celrep.2026.117997_bib110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/0008-5472.CAN-12-3583","article-title":"Dramatic antitumor effects of the dual MET\/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer","volume":"74","author":"Kawada","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib111","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1541-7786.MCR-16-0172","article-title":"MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma","volume":"14","author":"Bell","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib112","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.18632\/oncotarget.24488","article-title":"Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors","volume":"9","author":"Konicek","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2026.117997_bib113","doi-asserted-by":"crossref","first-page":"e930","DOI":"10.1634\/theoncologist.2018-0411","article-title":"First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer","volume":"24","author":"He","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.celrep.2026.117997_bib114","doi-asserted-by":"crossref","first-page":"e1628","DOI":"10.1634\/theoncologist.2020-0520","article-title":"Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings","volume":"25","author":"Saleh","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.celrep.2026.117997_bib115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib116","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2016-02-698704","article-title":"Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo","volume":"128","author":"Kosciuczuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117997_bib117","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.3390\/ijms22189953","article-title":"Therapeutic Targeting of the Gas6\/Axl Signaling Pathway in Cancer","volume":"22","author":"Tanaka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.celrep.2026.117997_bib118","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/1471-2407-9-411","article-title":"PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells","volume":"9","author":"Crosswell","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib119","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/0008-5472.CAN-05-2623","article-title":"Increased Frequency of Aberrations in the p53\/MDM2\/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse","volume":"66","author":"Carr","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib121","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1158\/1538-7445.AM2024-4555","article-title":"Abstract 4555: c-Met\/AXL crosstalk in mediating therapeutic resistance in renal cell carcinoma","volume":"84","author":"Sabarwal","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib122","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/carcin\/bgi192","article-title":"The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness","volume":"26","author":"Hecht","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.celrep.2026.117997_bib123","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1517\/14728222.2014.867946","article-title":"Therapeutic targets for neuroblastomas","volume":"18","author":"Brodeur","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.celrep.2026.117997_bib124","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ydbio.2016.08.016","article-title":"Transcriptional targets of TWIST1 in the cranial mesoderm regulate cell-matrix interactions and mesenchyme maintenance","volume":"418","author":"Bildsoe","year":"2016","journal-title":"Dev. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib125","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/onc.2015.434","article-title":"ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT","volume":"35","author":"Debruyne","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117997_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273280","article-title":"Whole exome sequencing of high-risk neuroblastoma identifies novel non-synonymous variants","volume":"17","author":"Przyby\u0142a","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117997_bib127","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10555-021-10001-7","article-title":"Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology","volume":"41","author":"Rozen","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.celrep.2026.117997_bib128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s42003-021-02958-6","article-title":"TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth","volume":"5","author":"Sepporta","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.celrep.2026.117997_bib129","article-title":"Identification of signalling pathways activated by Tyro3 that promote cell survival, proliferation and invasiveness in human cancer cells","volume":"28","author":"Al Kafri","year":"2021","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119182","article-title":"Targeting DDR1 with novel synthesized antagonists delays cellular aging and enhances wound healing in mesenchymal stem cells","volume":"197","author":"Nada","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.celrep.2026.117997_bib131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hon.3076","article-title":"DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: Implications for clonal evolution and disease progression","volume":"41","author":"Lagunas-Rangel","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.celrep.2026.117997_bib132","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.radonc.2011.08.013","article-title":"The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination","volume":"101","author":"Zhao","year":"2011","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.celrep.2026.117997_bib133","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41416-023-02208-y","article-title":"Genomic ALK alterations in primary and relapsed neuroblastoma","volume":"128","author":"Rosswog","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117997_bib134","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1158\/1078-0432.CCR-20-4224","article-title":"Activity of Crizotinib in Patients with ALK-Aberrant Relapsed\/Refractory Neuroblastoma: A Children\u2019s Oncology Group Study (ADVL0912)","volume":"27","author":"Foster","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/cdd.2017.41","article-title":"mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism","volume":"24","author":"Lampada","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.celrep.2026.117997_bib136","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41419-022-04799-5","article-title":"HGF\/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR\/NGF axis","volume":"13","author":"Qin","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.celrep.2026.117997_bib137","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/sj.onc.1210938","article-title":"Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo","volume":"27","author":"Johnsen","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2026.117997_bib138","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1541-7786.MCR-17-0607","article-title":"Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition","volume":"16","author":"Fang","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117997_bib139","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41419-025-08321-5","article-title":"FOXM1 induces therapy resistance and inhibits apoptosis in a variety of human cancers","volume":"17","author":"Raghuwanshi","year":"2026","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.celrep.2026.117997_bib140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39030","article-title":"Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12\/13","volume":"7","author":"Zeng","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2026.117997_bib141","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.1121119109","article-title":"Functional genomics identifies therapeutic targets for MYC-driven cancer","volume":"109","author":"Toyoshima","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117997_bib142","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.canlet.2014.11.056","article-title":"TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma","volume":"357","author":"Selmi","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.celrep.2026.117997_bib143","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2159-8290.CD-17-0993","article-title":"MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification","volume":"8","author":"Zimmerman","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117997_bib144","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117997_bib145","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1038\/s41598-024-56831-7","article-title":"CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer","volume":"14","author":"Lu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117997_bib146","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2020.09.011","article-title":"CDK12\/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer","volume":"495","author":"Li","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.celrep.2026.117997_bib147","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14737140.2017.1364995","article-title":"Anti-GD2 immunotherapy for neuroblastomas","volume":"17","author":"Sait","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.celrep.2026.117997_bib150","article-title":"Automatic end-to-end analysis of high-throughput in vitro cell culture screening by HTSplotter","author":"Nunes","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.celrep.2026.117997_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113800","article-title":"A Comprehensive Platform for the Analysis and Visualization of Structural Genomic Variation","volume":"9","author":"Sante","year":"2014","journal-title":"PLoS One"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726010752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726010752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:03:37Z","timestamp":1792760617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726010752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":149,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2211124726010752"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117997","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologically targeting CDK12 induces BRCAness and synergizes with merestinib to exacerbate DNA damage in high-risk neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117997"}}